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Protein tyrosine kinases are mediators of growth factor-induced
cell proliferation in many cancers, and the type I receptor tyrosine
kinase (RTK-I) family of receptors have particularly important
roles in ovarian cancer (Simpson et al, 1995). The first identified
member of this family, the epidermal growth factor (EGF) receptor
(c-erbB-1), is a transmembrane glycoprotein that mediates the
mitogenic response to the EGF family of ligands that includes both
EGF and transforming growth factor a (TGF-a) (Carpenter, 1987).
On activation, the EGF receptor phosphorylates tyrosine residues
on its C-terminal tail and may also interact with other members of
the RTK-I family (c-erbB2, c-erbB3 and c-erbB4). These intra-
cellular phosphorylations initiate signalling cascades which eventu-
ally result in gene activation (Egan and Weinberg, 1993).
The EGF receptor is reported to be present in between 33% and
75% of ovarian cancers (Bauknecht et al, 1988, 1993; Battaglia et
al, 1989; Berchuck et al, 1991; Morishige et al, 1991; Owens et al,
1991; Henzen-Logmans et al, 1992), and has been implicated in
both the growth and progression of this disease. Ovarian adenocar-
cinomas that express increased concentrations of the EGF receptor
are associated with poor survival (Bauknecht et al, 1988; Battaglia
et al, 1989; Foekens et al, 1990; Berchuck et al, 1991; Scambia et
al, 1992; Bartlett et al, 1996), and both TGF-a and EGF have been
shown to stimulate growth of ovarian cancer cells in culture
(Morishige et al, 1991; Rodriguez et al, 1991; Scambia et al, 1991;
Crew et al, 1992; Zhou and Leung, 1992).
Enzymatic activity of the intracellular tyrosine kinase domain of
the EGF receptor is essential for signal transduction (Chen et al,
1987; Honegger et al, 1987). These signalling pathways that
mediate cell proliferation therefore represent novel target sites for
anti-cancer drug development. The potential use of protein tyro-
sine kinase inhibitors as antiproliferative agents was first proposed
in 1981 for quercetin (Graziani et al, 1981). Recently, many more
specific and potent inhibitors have been identified (Fry et al,
1994a; Levitzki and Gazit, 1995), and one of these, ZM 252868
[PD 153035; 4(3-bromoanilino)-6,7-dimethoxyquinazoline], is a
potent inhibitor of the EGF receptor (Fry et al, 1994b; Wakeling et
al, 1996; Jones et al, 1997). In this study, we have assessed the
ability of the drug to inhibit ovarian cancer cell growth and tyro-
sine phosphorylation on the EGF receptor in order to obtain
evidence that ovarian cancer might be one of the disease types
which could be amenable to an EGF receptor-targeted strategy.
MATERIALS AND METHODS
Cell lines
The human ovarian carcinoma cell lines PE01 and PE04 were
established and characterized as previously described (Langdon et
al, 1988). The PE01CDDP variant was established by in vitro expo-
sure of the PE01 line to cisplatin (Beattie et al, 1993). The SKOV-
3 ovarian carcinoma cell line was obtained from the European
Collection of Animal Cell Cultures, Porton Down, UK. All these
lines were routinely cultured at 37°C in an atmosphere of 5%
carbon dioxide/95% air in RPMI-1640 containing phenol red indi-
cator. The medium was supplemented with 10% fetal calf serum
(FCS), L-glutamine (2 mM), penicillin (100 IU ml—1) and strepto-
mycin (100 mg ml—1).
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Log-phase PE01, PE01CDDP, PE04 and SKOV-3 ovarian cancer
cells were harvested by trypsinization and seeded in 24-well plates
(Falcon) at a density of 2.5 ´ 104 cells per well, or in the case of the
SKOV-3 cells at 1.25 ´ 104 cells per well, in quadruplicate in
RPMI-1640 (Gibco BRL, Paisley, UK) containing 10% heat-
inactivated FCS and penicillin (100 U ml—1) and streptomycin
(100 mg ml—1). Cells were maintained routinely at 37°C in a humid-
ified atmosphere of 5% carbon dioxide in air. After 24 h, the media
were removed and, after two phosphate-buffered saline (PBS)
washes, replaced by phenol-red-free RPMI-1640 containing
5% double charcoal-stripped fetal calf serum (DCS FCS), peni-
cillin (100 U ml—1), streptomycin (100 mgm l —1) and glutamine
(2 mmol l—1). Phenol-red-free medium was used because the PE01
and PE04 are growth-stimulated by oestrogen, and the absence of
the oestrogenic indicator provides a cleaner system in which to
observe TGF-a modulations. After a further 24 h, media were
removed and replenished by fresh phenol-red-free RPMI plus
additives. Phenol-red-free medium was used because the PE01 and
PE04 cell lines are growth stimulated by oestrogen and phenol red
has oestrogenic activity. The tyrosine kinase inhibitor ZM 252868
was added 30 min before the addition of TGF-a (10—10 M); this
time point was designated day 0. Thereafter, fresh medium was
added on day 2. Cells were harvested on day 5 and counted using a
Coulter counter (Coulter Electronics, Luton, UK).
Phosphotyrosine Western blotting
PE01, PE01CDDP, PE04 and SKOV-3 ovarian cancer cells were
grown to 80% confluence in 25 cm2 flasks (Falcon) in the presence
of RPMI-1640 containing 10% FCS. After two washes with PBS,
phenol-red-free RPMI-1640 containing 5% DCS FCS in the pres-
ence or absence of ZM 252868 (0.03—3.0 mM) was added, and the
cells were incubated overnight at 37°C in a humidified atmosphere
of 5% carbon dioxide in air. Cells were then incubated for 30 min in
fresh RPMI ± ZM 252868. RPMI ± ZM 252868 was replenished
and incubated for a further 5 min in the presence or absence of
TGF-a (10—10 M). Cells were then washed twice in ice cold PBS,
lysed, detached from the flasks and spun at 15 000 r.p.m. at 4°C.
Protein content of the resulting supernatant was determined by
Bradford assay (Bradford, 1976) and stored at —80°C before
phosphotyrosine Western blotting. Protein samples were denatured
at 95°C for 5 min in buffer containing sodium dodecyl sulphate
(SDS) and mercaptoethanol, then 75 mg of protein was loaded into
each lane on a 7.5% polyacrylamide gel. After polyacrylamide gel
electrophoresis, proteins were transferred to Immobilon-P
polyvinylidene fluoride (PVDF) membrane using a wet transfer
system (BioRad Trans Blot Cell). The transfer was carried out
overnight at 4°C with 30 V followed by 60 V for 2 h. Proteins were
detected using a specific anti-phosphotyrosine mouse monoclonal
antibody, p-Tyr (PY20) (Santa Cruz Biotechnology), in conjunction
with a chemiluminescence Western Blotting Kit (Boehringer
Mannheim). Membranes were blocked in 1% blocking reagent
(supplied with kit and containing 10% purified casein protein in
maleic acid) diluted in TBS (Tris-buffered saline pH 7.5) for 1 h at
room temperature. The membrane was incubated with primary anti-
body (PY20) diluted to 1 mg ml—1 in 0.5% blocking reagent in TBS
overnight at 4°C, washed three times for 5 min in TBS-T (TBS with
0.1% Tween 20), twice for 5 min in TBS, incubated twice for 5 min
in 0.5% blocking agent in TBS and treated with secondary antibody
for 1 h at room temperature. The secondary antibody (anti-mouse
IgG-POD/anti-rabbit IgG-POD) was diluted in 0.5% blocking solu-
tion in TBS to 160 mU ml—1. Finally, the membrane was washed
once again, three 5-min washes in TBS-T, then three 5-min washes
in TBS. After incubation in luminescence substrate solution, light
emission was detected on radiographic film.
Epidermal growth factor receptor tyrosine kinase
enzyme assay
Epidermal growth factor receptor tyrosine kinase enzyme activity
was measured in the ovarian cancer cell lines using a Biotrak assay
(Amersham, UK). Briefly, membrane preparations were obtained
from cells grown to 70% confluence in 175 cm2 flasks. Lysis buffer
(50 mM Tris, 1 mM magnesium chloride, 2 mM EDTA, 20 mg ml—1
soybean trypsin inhibitor, 50 mg ml—1 PMSF) was added (7 ml per
175 cm2 flask) to cell monolayers. Lysates were homogenized and
centrifuged at 3000 r.p.m. for 10 min and supernatants then
centrifuged at 100 000 g for 30 min to obtain membrane prepara-
tions. These were resuspended in solubilization buffer [50 mM
Hepes, 20% glycerol, 1% Triton-X, 0.1% bovine serum albumin
(BSA), 0.05% sodium azide] and stored at —80°C until assayed.
Assay reactions included membrane preparation (10 ml), EGF (5
ml; 1.5 ´ 10—6 M), substrate peptide solution (10 ml; peptide
1.5 mM, 135 mM Hepes, 300 mM sodium orthovanadate, 3 mM
dithiothreitol, 0.15% Triton X-100, 6% glycerol and 0.05%
sodium azide pH 7.4) and magnesium [g-32P]ATP buffer (5 ml;
9.25 kBq, 0.25 mCi per tube). The reaction was initiated by addi-
tion of magnesium [g-32P]ATP buffer and allowed to proceed for
30 min. The reaction was terminated by addition of 300 mM
orthophosphoric acid (10 ml) containing carmosine. The termi-
nated reaction mixture 30 ml was then pipetted onto a paper disc
which was washed with 1% acetic acid (250 ml) and water. The
disc was placed into a scintillation vial and counted in a Packard
1900 CA Tri-Car scintillation analyser.
In the presence of enzyme sample and EGF, the 32P counted on the
papers is the sum of non-specific [32P]ATP binding, specific binding
of phosphorylated peptide and binding of phosphorylated proteins in
the cell extract (A). In the absence of EGF and presence of enzyme,
the 32P counted on the papers is the sum of non-specific [32P]ATP
binding and non-EGF-dependent tyrosine kinase phosphorylation of
the peptide and cell extract proteins (B). EGF-dependent tyrosine
kinase activity is, therefore, obtained from (A — B).
Determination of EGF-R, c-erbB2 and c-erbB3 by
immunofluorescence
The presence of EGF receptor, c-erbB2 and c-erbB3 proteins was
identified on PE01, PE01CDDP, PE04 and SKOV-3 cells by
immunofluorescence using a flow cytometer. The following anti-
bodies were used: EGF receptor, clone EGFR1 (ICRF, Clare Hall,
London UK); c-erbB2, clone CB11 (Novocastra); and c-erbB3,
clone RTJ1 (Novocastra). Cells were harvested by trypsinization
(in pilot experiments found to be less damaging than cell
scraping), washed in cold PBS containing 5% FCS, and aliquots of
approximately 106 cells were then incubated for 60 min with anti-
body. For c-erbB2 and c-erbB3 staining, 1% saponin (BDH, Poole,
Dorset, UK) was added to the cells before antibody addition
(Brotherick et al, 1995). Cells were then washed in PBS/FCS and
incubated with sheep anti-mouse fluorescein isothiocyanate
(FITC, 1:20) for 60 min and washed twice with PBS/FCS. Cells
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were resuspended in PBS and analysed on the FACScan flow
cytometer.
RESULTS
Effects of tyrosine kinase inhibitor on TGF-a-modulated
growth of ovarian cancer cells
The PE01, PE04, SKOV-3 and PE01CDDP cell lines were treated
with ZM 252868 for 5 days in the absence or presence of TGF-a
(10—10 M) (Figures 1 and 2). In the absence of TGF-a, ZM 252868
inhibited growth of PE01 cells at concentrations equal to or greater
than 0.03mM. Addition of TGF-aproduced an approximately
150% increase in control cell number; this increase was abolished
by ZM 252868 at concentrations equal to or greater than 0.3mM
(Figure 1A). For PE04 cells, ZM 252868 inhibited growth at
0.3mM(Figure 1B). Addition of TGF-aproduced a 100% increase
in cell number and this stimulation was partially reversed at
0.03mMand completely blocked at 0.3mM(Figure 1B). For
SKOV-3 cells, ZM 252868 inhibited growth at 0.1mM. Addition of
TGF-aproduced an approximately 130% increase in control cell
number; this increase was abolished by ZM 252868 at concentra-
tions equal to or greater than 0.1mM(Figure 1C).
Addition of TGF-ato PE01CDDP cells produces growth inhibi-
tion (Figure 2). ZM252868 (0.03—3.0mM) reversed the TGF-a-
induced growth inhibition, with a total reversal of this effect
observed at concentrations ‡0.1mM. Basal cell growth was also
significantly increased (P< 0.001) after the addition of ZM
252868 at 0.03mM, but was not significantly different from control
at concentrations ‡0.1mM(Figure 2).
Activation of EGF receptor and c-erbB2 by TGF-a
Western blotting with an anti-phosphotyrosine antibody (PY20)
showed that, after exposure to TGF-a, both the EGF receptor and
c-erbB2 protein were phosphorylated on tyrosine residues in PE01
cells. The identity of bands was confirmed in parallel experiments
using antibodies specific for the EGF receptor and c-erbB2 (data
not shown). The time course of activation by TGF-ais illustrated
in Figure 3 for the PE01 cell line and occurred within 1min of
addition of the growth factor (Figure 3A). Investigation of the
concentration range 10—12—10—8 Mindicated that phosphorylation
increased with increasing concentrations of TGF-aafter a 5-min
exposure (Figure 3B). This latter concentration (10—8 M) was
selected for experiments with ZM 252868.
Inhibition of tyrosine phosphorylation of the EGF
receptor by ZM 252868
The cell lines were treated with ZM 252968 for 5min in the
presence or absence of 10—8 MTGF-a. TGF-aincreased tyrosine
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Figure 1Effect of ZM 252868 on the basal and TGF-a-stimulated growth of
the PE01, PE04 and SKOV-3 ovarian cancer cell lines. Inhibitor was added in
the absence (n) or presence of TGF-a(10–10 M) ( ). Significantly different
from appropriate control: ***P < 0.001; **P < 0.01; *P < 0.05; NS, not
significant (Student’s t-test)
Figure 2Effect of ZM 252868 on the basal and TGF-a-inhibited growth of
PE01CDDP ovarian cancer cells. Inhibitor was added in the absence (n) or
presence of TGF-a(10–10 M) ( ). Significantly different from appropriate
control: ***P < 0.001; **P < 0.01; *P < 0.05; NS, not significant (Student’s
t-test)
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Figure 3Western blotting of phosphotyrosine residues in PE01 cells using
the PY20 antibody after addition of TGF-a. (A) Time course of TGF-a
activation in PE01 cells. (B) Effect of TGF-aconcentration on EGF receptor
activation in PE01 cells (after 5min). The upper signal shown corresponds to
the c-erbB protein and the lower signal to the EGF receptor. In untreated
cells, only c-erbB2 is tyrosine phosphorylated, but after addition of TGF-a
phosphotyrosine signals are seen on the EGF receptor and are increased on
c-erbB2 compared with no treatmentInhibition of ovarian cancer by ZM 252868 1101
British Journal of Cancer (1999) 79(7/8), 1098–1103 © Cancer Research Campaign 1999
phosphorylation of both the EGF receptor and c-erbB2 in all four
cell lines consistent with ligand activation via the EGF receptor
and heterodimerization with c-erbB2 (Figure 4). At concentrations
of 0.3, 1 and 3 mM, the EGF receptor phosphorylation was
completely blocked. The c-erbB2 phosphorylation was also
decreased, but to a lesser degree in all four lines (Figure 4).
In the absence of TGF-a, only c-erbB2 phosphorylation was
observed in untreated cells (Figure 4). This was also decreased
after addition of ZM 252868, but only at higher concentrations of
inhibitor.
Epidermal growth factor receptor tyrosine kinase
inhibitory activity of ZM 252868
The EGF receptor tyrosine kinase enzyme activity was investi-
gated by an assay which measures the transfer of the g-phosphate
of adenosine 5¢ triphosphate to the tyrosine group on a peptide
which is specific for EGF receptor tyrosine kinase (Amersham).
EGF, which is known to be equipotent with TGF-a in these
systems, was used to activate the receptor. Addition of EGF
resulted in a 22% increase in phosphorylation in PE01 cells, a 41%
increase in phosphorylation in PE01CDDP cells and a 49% increase
in phosphorylation in SKOV-3 cells (Table 1). For PE04 cells, a
9% increase in phosphorylation was observed, but this did not
achieve statistical significance. These increases were completely
reversed by the addition of ZM 252868 (3 mM) (Table 1). In a
subsequent experiment with PE01 cells, the 33% increase in
phosphorylation produced by EGF was blocked by ZM 252868 at
concentrations of 0.03, 0.3 and 3 mM (Table 2). The basal level of
EGF receptor activity was lower in this experiment, reflecting an
unknown variable, however intra-assay changes in activity after
addition of ligand and blockade by inhibitor were reproducible.
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Figure 4 Western blotting of phosphotyrosine in ZM 252868-treated
ovarian cancer cells. Blots are shown for the PE01, PE04, SKOV-3 and
PE01CDDP cell lines. The upper signal shown corresponds to the c-erbB2
protein and the lower signal to the EGF receptor. In untreated cells, only
c-erbB2 is tyrosine phosphorylated, but after addition of TGF-a
phosphotyrosine signals are seen on the EGF receptor and are increased on
c-erbB2 compared with no treatment. ZM 252868 was added 30 min before
TGF-a addition. Lysates were collected after 5 min exposure to TGF-a. At
the concentrations shown, ZM 252868 eliminated the EGF phosphotyrosine
signal associated with the EGF receptor and reduced the signal associated
with c-erbB2
Table 1 ZM 252868 inhibition of EGF receptor tyrosine kinase activity in
ovarian cancer cell lines
Tyrosine kinase activity (pmol phosphate min–1)
Cell line –EGF +EGF (0.5 mM) +EGF (0.5 mM)
Control +ZM 252868 (3 mM)
PE01 5.93 ± 0.16 7.22* ± 0.38 4.92 ± 0.41
PE01CDDP 6.24 ± 0.23 8.78* ± 0.50 5.67 ± 0.07
SKOV-3 3.56 ± 0.11 5.32* ± 0.45 3.82 ± 0.15
PE04 5.44 ± 0.52 5.92 ± 0.33 5.31 ± 0.89
Values shown are means ± standard errors of 4–6 replicates in a typical
experiment. *Significantly different from control P < 0.05 (Student’s t-test).
Table 2 Effect of varying concentrations of ZM 252868 on EGF receptor
tyrosine kinase activity in PE01 cells
EGF ZM 252868 Activity
(mM)( mM) (pmol phosphate min–1)
0 0 3.57 ± 0.1
0.5 0 4.74* ± 0.35
0.5 0.03 3.64 ± 0.06
0.5 0.3 3.59 ± 0.12
0.5 3.0 3.40 ± 0.17
Values shown are means ± standard error of eight replicate values.
*Significantly different from control (P = 0.006, Student’s t-test).
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Figure 5 Flow cytometric analysis of c-erbB receptor expression in ovarian
cancer cell lines. Cells were incubated with anti-erbB antibodies (EGF
receptor, clone EGFR1; c-erbB2, clone CB11; anti-erbB3, clone RTJ1)
followed by sheep anti-mouse fluorescein isothiocyanate. Cells were then
analysed on a FACscan. Representative profiles are shown1102 BJB Simpson et al
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Expression of erbB receptors in ovarian cancer cells
Because the activated EGF receptor has the potential to
heterodimerize with other members of the c-erbB family, it was of
interest to know the relative levels of expression of these proteins
in the cell lines under study. The relative expression of EGF recep-
tors, c-erbB2 and c-erbB3 in PE01, PE04, SKOV-3 and PE01CDDP
was measured by immunofluorescence on a FACscan, and repre-
sentative profiles are shown in Figure 5 and mean values obtained
from three independent experiments are shown in Figure 6. The
SKOV-3 cell line possessed the greatest number of EGF receptors
and PE04 the least. SKOV-3 cells also had a two- to threefold
greater expression of c-erbB2 than the other three line, whereas all
four lines had comparable levels of c-erbB3 (Figure 6).
DISCUSSION
ZM 252868 (also known as PD 153035) is a potent inhibitor of the
EGF receptor, with an IC50 value of 29 pM against the purified
tyrosine kinase in A431 cells (Fry et al, 1994). Against other
human tumour cell lines, including breast, prostatic, cervical and
colon cancer cell lines, the compound has been reported to inhibit
growth at concentrations ‡ 75 nM (Bos et al, 1996; Jones et al,
1997), and this is similar to the observations in these ovarian
cancer cell lines wherein 100 nM inhibited the TGF-a-stimulated
growth of PE01, PE04 and SKOV-3 cells. All three ovarian cancer
lines have comparable levels of EGF receptor and ZM 252868
showed a similar degree of potency, with complete inhibition of
growth being obtained at concentrations between 0.1 and 0.3 mM.
At these concentrations, ZM 252868 inhibited TGF-a-activated
tyrosine phosphorylation at the EGF receptor and partially inhib-
ited phosphorylation at c-erbB2 consistent with its proposed mech-
anism of action. Because the activated EGF receptor interacts with
and transphosphorylates the c-erbB2 receptor, it is not surprising
that phosphorylation levels are reduced at this protein as well as at
the EGF receptor, though direct effects by ZM 252868 on c-erbB2
cannot be ruled out and this is in line with previous studies (Bos et
al, 1996). Although we did not investigate the specificity of ZM
252868 for the EGF receptor in this study, previous investigations
have demonstrated its ability to specifically block TGF-a or EGF-
stimulated growth as opposed to platelet-derived growth factor or
insulin-like growth factor-stimulated growth (Fry et al, 1994b;
Jones et al, 1997). Data obtained from the EGF receptor tyrosine
kinase activity assay confirmed that inhibition of kinase activity
occurred at growth inhibitory concentrations in PE01 cells.
Although it cannot always be assumed that EGF receptor activa-
tion necessarily leads to a mitogenic response, the data obtained in
the PE01, PE04 and SKOV-3 lines suggests that it can be and that
the inhibitor blocks this action. However, the data obtained using
the PE01CDDP model indicate that TGF-a activation may also be
associated with growth inhibitory effects. TGF-a treatment
produced growth inhibition in this cell line (Simpson et al, 1998),
and ZM 252868 was able to antagonize this growth effect with
associated reduction in EGF receptor phosphotyrosine and kinase
activity. This cell line was derived from the PE01 cell line after
exposure to cisplatin (Beattie et al, 1993) and, as demonstrated
here, the changed growth response is not simply a result of altered
erbB receptor numbers. We are currently investigating down-
stream responses that can be specifically associated with either
growth stimulation or growth inhibition because these may help
indicate the type of growth response elicited by TGF-a.
In the absence of TGF-a, ZM 252868 inhibited the growth of
PE01, PE04 and SKOV-3 cells and stimulated growth of PE01CDDP
cells compared with no treatment. This would be consistent with
inhibition of the action of autocrine production of TGF-a or other
EGF receptor-activating ligands which are stimulating the EGF
receptor in the absence of added factors. Evidence to support such
a process has been obtained from other ovarian cancer models,
wherein antibodies to the EGF receptor or to TGF-a have been
shown to block growth consistent with TGF-a/EGF receptor
autocrine pathways being functional (Morishige et al, 1991).
Blockade of signalling via the EGF receptor appears a
promising growth inhibitory strategy. Using these cell lines, we
have recently investigated other approaches to neutralizing this
receptor. Antibody blockade of the EGF receptor produces similar
growth-reversing effects in the PE01 and PE01CDDP cell lines
(Simpson et al, 1998), whereas antisense knockout of EGF
receptor mRNA in PE01 cells also produces growth inhibition
(Simpson et al, 1996). Relatively small structures such as ZM
252868 may, however, have improved pharmacokinetic properties
compared with antibody or antisense delivery. Although this
compound has demonstrated transient reduction of EGF receptor
tyrosine phosphorylation in A431 xenografts, this was insufficient
to produce growth inhibition in vivo (Kunkel et al, 1996). Closely
related analogues from this class of agents with improved pharma-
cokinetic properties and which are active against in vivo models
have now been developed (Woodburn et al, 1996, 1997), and an
analogue is currently undergoing phase I studies in the UK. These
data are the first to report that inhibitors of this class could have
activity in ovarian cancer systems, and would indicate that this
disease would be a suitable system for clinical investigations. It
will be important to define tumours in the clinical setting whose
growth is dependent on the EGF receptor and which are being
driven by activating ligands such as TGF-a and EGF. Tyrosine
phosphorylation of the EGF receptor in clinical specimens of
ovarian cancer can be readily identified, and it seems likely that
those tumours in which activation is found represent the target
population for this inhibitor.
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Figure 6 c-ErbB receptor expression in ovarian cancer cell lines. Cells
were incubated with anti-erbB antibodies (EGF receptor, clone EGFR1;
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